ILSI-Biomed Israel

Six trends that will change the fundamentals of pharmaceutical distribution

The latest report in the Pharma 2020 series from PwC US outlines six trends that will fundamentally change the way pharmaceutical companies make and distribute products. “The current pharmaceutical supply chain worked well when the ‘blockbuster’ paradigm prevailed, but pharma’s focus in a post-health reform world is shifting from products to patients, and their supply chain processes need to adopt the speed and agility of other, more consumer-oriented industries such as consumer electroni...

JSBarkats Sponsors 2011 US/Israel Venture Summit in New York

NEW YORK, March 22, 2011 (GLOBE NEWSWIRE) -- JSBarkats PLLC ("JSBarkats") announced today that it will be sponsoring the 2011 US/Israel Venture Summit in New York, March 29th -- 30th, 2011. The US/Israel Venture Summit, presented by youngStartup Ventures, is the premier gathering where cutting-edge Israeli startups meet top venture capitalists, angel investors, Corporate VCs and investment bankers from throughout North America. See http://www.youngstartup.com/usisrael2011/overview.php. ...

Meet the speakers: Francois Maisonrouge, Senior Managing Director, Evercore Partners.

Francois Maisonrouge is a Senior Managing Director in advisory business with 25 years of relevant experience. At Evercore, Mr. Maisonrouge was involved in advising Wyeth on its sale to Pfizer, Sanofiaventis on its purchase of Merck's 50% stake in Merial including an option to potentially merge Merial with Intervet / Schering-Plough Animal Health in the future, TPG on its acquisition of IMS Health, De Ruiter on its sale to Monsanto, Bracco on its acquisition of E-Z-Em, and the sale of Op...

PROLOR BIOTECH SIGNS EXCLUSIVE LICENSE AGREEMENT WITH YEDA FOR ANTI-OBESITY APPLICATIONS

PROLOR Biotech, Inc., (NYSE Amex: PBTH), announced that it has entered into a definitive license agreement with Yeda Research and Development Company Ltd. for novel technology utilized in the development of long-acting therapeutic peptides and small molecules, termed Reversible PEGylation. The Reversible PEGylation technology has been shown in animal models to significantly enhance the half-life and improve the biological activity of a variety of peptides and small molecules, including the diab...

Rachel Abramovitz Joins JSBarkats PLLC As The Chair Of The Life Sciences Practice

JSBarkats PLLC ("JSBarkats") announced today that Rachel Abramovitz, an experienced corporate attorney, joined the firm as a partner. Rachel has 15 years experience practicing law, including 10 years experience in the pharmaceutical and biotech industries. In addition to supporting the corporate and Israeli practice groups, Rachel will be leading the life sciences group in the firm. " We are pleased to be able to support our life sciences clients with a full range of legal services including IP,...

Israel: America’s Technology Farm System

In the accompanying video that’s just under 30 minutes long, Steve Forbes personally interviews George Gilder for an episode of Intelligent Investing. At about the 6:30 mark, Forbes asks Gilder about the companies he feels are at the forefront of leading edge technologies today and Gilder begins talking about Israel, whose companies are “…genius under the gun…a very productive environment.” In the ensuing exchange, Forbes probes Gilder on his claim that Israel is “a functional part of th...

Foamix Announces Phase II Clinical Trial of Topical Minocycline Foam for Rosacea

The first-in-class topical Minocycline product, protected by 4 patent applications, is directed for the treatment of Rosacea, Acne, Skin Infections and Chronic Wounds. Foamix Ltd., a clinical-stage specialty pharmaceutical company focused on the development of proprietary dermatological and gynecologic topical products, today announced enrollment of the first patient in a Phase II trial of its Topical Minocycline Foam. The double-blind, placebo controlled dose range finding study aims to ...

PwC: Israel being overtaken in medical devices

Israel's start-ups are considered one of the country's competitive advantages in the global high-tech and life sciences industries. However, a new report by PricewaterhouseCoopers LLP (PwC) says that emerging economies are breathing down Israel's neck and may have already passed it. PwC says in its “Race for Global Leadership: Medical Technology Innovation Scorecard” that start-up activity in Israel's medical devices sector is less than in countries such as India, China, and Brazil. PwC ...

Junior Sales Manager To promote sales activity worldwide in the field of Medical Devices

Requirements: • Bachelor Degree with 2 years sales experience in the health care market •Experienced in dealing with operating room staff, orthopedic implants, and purchasing personal – an advantage •Ability to work independently with minimal direction •Excellent written and verbal communication skills, ability to present information to various audiences. •Passionate about medical devices and technology, keen interest in learning the ever-evolving healthcare market. Position requir...

Molecular imaging to diagnose, monitor and treat disease

Molecular probes from Israel's Aposense show areas of disease on a cellular level and can even provide a picture that reveals the efficacy of chemotherapy. Israeli biotech company Aposense offers a futuristic way of diagnosing, monitoring and treating disease through molecules designed to detect cell death (apoptosis). While apoptosis is a universal process in cell biology, it plays a role in most medical disorders. Targeting cells undergoing apoptosis, for imaging or delivering therapy, can ...